NCT01316328

Brief Summary

The single shot partial breast irradiation (SSPBI) trial was designed as a prospective Phase II "single-arm study". The use of a single dose tumor bed is expected to be very effective in terms of tumor control, but it could increase the incidence of radiation induced erythema. Therefore, the investigators assumed that a decreased DNA repair capability, as well as a reduced detoxification of the damage caused by oxidative stress could explain the increased acute toxicity, i.e. a higher incidence of erythema after a single dose. For this reason the investigators decided to investigate SNPs of genes involved in antioxidant and DNA damage repair pathways such as GST, XRCC1, XRCC3 and RAD51. The investigators assumed an erythema rate of 20% and 54% in patient groups at low and high risk, respectively, (groups were identified based on the absence/presence of the above polymorphisms alone or in combination), thus the minimum sample size was 56 patients with α=0.05, 2-tailed test and a power of the study of 80%.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
Completed

Started May 2010

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2010

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2010

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

March 15, 2011

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 16, 2011

Completed
Last Updated

March 16, 2011

Status Verified

December 1, 2010

Enrollment Period

7 months

First QC Date

March 15, 2011

Last Update Submit

March 15, 2011

Conditions

Keywords

toxicity after single shot partial breast irradiation (SSPBI)

Study Arms (1)

BC patients after SSPBI

breast cancer (BC) patients following single shot partial breast irradiation (SSPBI) after breast conservative surgery

Eligibility Criteria

Age48 Years - 90 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

breast cancer (BC) patients following single shot partial breast irradiation(SSPBI) after breast conservative surgery

You may qualify if:

  • Age ≥ 48 years old with a life expectancy of at least 5 years
  • Post-menopausal status
  • Histologically proven, non lobular, adenocarcinoma of the breast
  • Primary tumours ≤ 3 cm
  • Negative surgical margins (≥ 2 mm)
  • Negative sentinel nodes or \< 4 positive axillary nodes
  • No extra-capsular extension
  • No previous radiotherapy

You may not qualify if:

  • multicentric disease
  • extended intraductal component (EIC \> 25%)
  • Paget's disease
  • lobular adenocarcinoma
  • distant metastases All the above criteria allow to identify patients at low risk of local recurrence.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Regina Elena NCI

Rome, Rome, 00144, Italy

Location

Related Publications (3)

  • Falvo E, Strigari L, Citro G, Giordano C, Boboc G, Fabretti F, Bruzzaniti V, Bellesi L, Muti P, Blandino G, Pinnaro P. SNPs in DNA repair or oxidative stress genes and late subcutaneous fibrosis in patients following single shot partial breast irradiation. J Exp Clin Cancer Res. 2012 Jan 24;31(1):7. doi: 10.1186/1756-9966-31-7.

  • Pinnaro P, Arcangeli S, Giordano C, Arcangeli G, Impiombato FA, Pinzi V, Iaccarino G, Soriani A, Landoni V, Strigari L. Toxicity and cosmesis outcomes after single fraction partial breast irradiation in early stage breast cancer. Radiat Oncol. 2011 Nov 11;6:155. doi: 10.1186/1748-717X-6-155.

  • Falvo E, Strigari L, Citro G, Giordano C, Arcangeli S, Soriani A, D'Alessio D, Muti P, Blandino G, Sperduti I, Pinnaro P. Dose and polymorphic genes xrcc1, xrcc3, gst play a role in the risk of articledeveloping erythema in breast cancer patients following single shot partial breast irradiation after conservative surgery. BMC Cancer. 2011 Jul 12;11:291. doi: 10.1186/1471-2407-11-291.

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

March 15, 2011

First Posted

March 16, 2011

Study Start

May 1, 2010

Primary Completion

December 1, 2010

Study Completion

December 1, 2010

Last Updated

March 16, 2011

Record last verified: 2010-12

Locations